Journal of Biological Chemistry · 2009 · 62 citations · 53 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructural BiologyEnzyme InhibitionLigand BindingPeptide ChemistryPeptide Drug DiscoveryProtein StructureProteolytic ProcessingParasite Invasion MechanismsPeptide Binding AffinityPeptide Lead OptimizationPeptide Structure - Activity RelationshipsPlasmodium FalciparumProteolytic Degradation Of PeptidesTargeting PeptidesTherapeutic Peptides
Apical membrane antigen 1 (AMA1) of the malaria parasite Plasmodium falciparum has been implicated in the invasion of host erythrocytes and is an important vaccine candidate. We have previously described a 20-residue peptide, R1, that binds to AMA1 and subsequently blocks parasite invasion. Because this peptide appears to target a site critical for AMA1 function, it represents an important lead compound for anti-malarial drug development. However, the effectiveness of this peptide inhibitor was limited to a subset of parasite isolates, indicating a requirement for broader strain specificity. Furthermore, a barrier to the utility of any peptide as a potential therapeutic is its susceptibility to rapid proteolytic degradation. In this study, we sought to improve the proteolytic stability and AMA1 binding properties of the R1 peptide by systematic methylation of backbone amides (N-methylation). The inclusion of a single N-methyl group in the R1 peptide backbone dramatically increased AMA1 affinity, bioactivity, and proteolytic stability without introducing global structural alterations. In addition, N-methylation of multiple R1 residues further improved these properties. Therefore, we have shown that modifications to a biologically active peptide can dramatically enhance activity. This approach could be applied to many lead peptides or peptide therapeutics to simultaneously optimize a number of parameters. Apical membrane antigen 1 (AMA1) of the malaria parasite Plasmodium falciparum has been implicated in the invasion of host erythrocytes and is an important vaccine candidate. We have previously described a 20-residue peptide, R1, that binds to AMA1 and subsequently blocks parasite invasion. Because this peptide appears to target a site critical for AMA1 function, it represents an important lead compound for anti-malarial drug development. However, the effectiveness of this peptide inhibitor was limited to a subset of parasite isolates, indicating a requirement for broader strain specificity. Furthermore, a barrier to the utility of any peptide as a potential therapeutic is its susceptibility to rapid proteolytic degradation. In this study, we sought to improve the proteolytic stability and AMA1 binding properties of the R1 peptide by systematic methylation of backbone amides (N-methylation). The inclusion of a single N-methyl group in the R1 peptide backbone dramatically increased AMA1 affinity, bioactivity, and proteolytic stability without introducing global structural alterations. In addition, N-methylation of multiple R1 residues further improved these properties. Therefore, we have shown that modifications to a biologically active peptide can dramatically enhance activity. This approach could be applied to many lead peptides or peptide therapeutics to simultaneously optimize a number of parameters. According to World Health Organization reports, almost half of the world human population is at risk of contracting malaria and approximately one million people are killed by this disease each year, most of which are young children. No reliable vaccine currently exists against Plasmodium falciparum, the parasite that causes the most severe form of malaria, and parasites are becoming increasingly resistant to previously effective pharmaceuticals (1Ridley R.G. Nature. 2002; 415: 686-693Crossref PubMed Scopus (707) Google Scholar). Thus, novel strategies to combat this disease are urgently required. Proteins involved in the erythrocytic stage of the parasite life cycle represent attractive targets for anti-malarial therapeutics, because this stage is responsible for the clinical symptoms of malaria. Apical membrane antigen 1 (AMA1) 3The abbreviations used are: AMA1, apical membrane antigen 1; MTBD, 7-methyl-1,5,7-triazabicyclo-[4.4.0]-dec-5-ene; Fmoc, N-(9-fluorenyl)methoxycarbonyl; PBS, phosphate-buffered saline; NOE, nuclear Overhauser effect; mAb, monoclonal antibody; HBTU, 2-(1H-benzotriazol-1-yl)-1,1,3,3,-tetramethyluronium hexafluorophosphate; DMF, dimethylformamide; DCM, dichloromethane; TNBS, 2,4,6-trinitrobenzenesulfonic acid; SPR, surface plasmon resonance. is an integral membrane protein common to all Plasmodium species that is thought to be important for parasite invasion of host red blood cells and hepatocytes (2Silvie O. Franetich J.F. Charrin S. Mueller M.S. Siau A. Bodescot M. Rubinstein E. Hannoun L. Charoenvit Y. Kocken C.H. Thomas A.W. van Gemert G.J. Sauerwein R.W. Blackman M.J. Anders R.F. Pluschke G. Mazier D. J. Biol. Chem. 2004; 279: 9490-9496Abstract Full Text Full Text PDF PubMed Scopus (256) Google Scholar, 3Triglia T. Healer J. Caruana S.R. Hodder A.N. Anders R.F. Crabb B.S. Cowman A.F. Mol. Microbiol. 2000; 38: 706-718Crossref PubMed Scopus (256) Google Scholar). The molecular mechanisms of the role of AMA1 in parasite invasion are unknown, but recent evidence suggests that it is involved in stabilizing the binding of the invasive form of the parasite to the erythrocyte (3Triglia T. Healer J. Caruana S.R. Hodder A.N. Anders R.F. Crabb B.S. Cowman A.F. Mol. Microbiol. 2000; 38: 706-718Crossref PubMed Scopus (256) Google Scholar, 4Mitchell G.H. Thomas A.W. Margos G. Dluzewski A.R. Bannister L.H. Infect. Immun. 2004; 72: 154-158Crossref PubMed Scopus (182) Google Scholar). In animal models, immunization with recombinant AMA1 induces protection from subsequent parasite challenge (5Anders R.F. Crewther P.E. Edwards S. Margetts M. Matthew M.L. Pollock B. Pye D. Vaccine. 1998; 16: 240-247Crossref PubMed Scopus (188) Google Scholar, 6Collins W.E. Pye D. Crewther P.E. Vandenberg K.L. Galland G.G. Sulzer A.J. Kemp D.J. Edwards S.J. Coppel R.L. Sullivan J.S. Morris C.L. Anders R.F. Am. J. Trop. Med. Hyg. 1994; 51: 711-719Crossref PubMed Scopus (165) Google Scholar), and it appears to be an essential protein in the parasite life-cycle as AMA1 genetic knockouts are not viable (3Triglia T. Healer J. Caruana S.R. Hodder A.N. Anders R.F. Crabb B.S. Cowman A.F. Mol. Microbiol. 2000; 38: 706-718Crossref PubMed Scopus (256) Google Scholar, 7Hehl A.B. Lekutis C. Grigg M.E. Bradley P.J. Dubremetz J.F. Ortega-Barria E. Boothroyd J.C. Infect. Immun. 2000; 68: 7078-7086Crossref PubMed Scopus (137) Google Scholar). AMA1 has therefore received much attention as a potential vaccine candidate or drug target. Although lacking the major structural diversity of some other P. falciparum antigens, AMA1 exhibits allelic variation that is a result of point mutations. Because immunization with AMA1 induces inhibitory antibodies that are less effective against heterologous parasite lines (8Healer J. Murphy V. Hodder A.N. Masciantonio R. Gemmill A.W. Anders R.F. Cowman A.F. Batchelor A. Mol. Microbiol. 2004; 52: 159-168Crossref PubMed Scopus (140) Google Scholar, 9Hodder A.N. Crewther P.E. Anders R.F. Infect. Immun. 2001; 69: 3286-3294Crossref PubMed Scopus (275) Google Scholar, 10Kennedy M.C. Wang J. Zhang Y.L. Miles A.P. Chitsaz F. Saul A. Long C.A. Miller L.H. Stowers A.W. Infect. Immun. 2002; 70: 6948-6960Crossref PubMed Scopus (221) Google Scholar), overcoming this diversity is a key hurdle in the development of AMA1-based anti-malarials. An immune response or drug would therefore ideally target a conserved region that is required for function. In addition to polyclonal and mAbs that bind to AMA1 and block parasite invasion in vitro (9Hodder A.N. Crewther P.E. Anders R.F. Infect. Immun. 2001; 69: 3286-3294Crossref PubMed Scopus (275) Google Scholar, 11Dutta S. Haynes J.D. Barbosa A. Ware L.A. Snavely J.D. Moch J.K. Thomas A.W. Lanar D.E. Infect. Immun. 2005; 73: 2116-2122Crossref PubMed Scopus (55) Google Scholar, 12Kocken C.H. van der Wel A.M. Dubbeld M.A. Narum D.L. van de Rijke F.M. van Gemert G.J. van der Linde X. Bannister L.H. Janse C. Waters A.P. Thomas A.W. J. Biol. Chem. 1998; 273: 15119-15124Abstract Full Text Full Text PDF PubMed Scopus Google Scholar), peptides that this antigen and inhibitory have been from peptide the surface of A.M. Masciantonio R. J.K. A. Anders R.F. M. Infect. Immun. 2005; 73: PubMed Scopus Google Scholar, F. Dluzewski A. A.M. Thomas A. L. Anders R.F. M. J. Biol. Chem. 2002; Full Text Full Text PDF PubMed Scopus Google Scholar). The most peptide inhibitor of invasion was the 20-residue peptide, R1 A.M. Masciantonio R. J.K. A. Anders R.F. M. Infect. Immun. 2005; 73: PubMed Scopus Google Scholar). that and as or can be for the of or as therapeutics The R1 peptide is an important lead compound for drug because its to block parasite that it targets a site critical for AMA1 function. However, of the parasite lines the R1 peptide was effective against the and and not or its utility as a therapeutic in its further barrier to the of peptides as pharmaceuticals is that are by and in to PubMed Scopus Google Scholar). was therefore of to the R1 peptide to improve its potential and properties. The methylation of backbone amides is one of peptide that has been to a lead This the of residues a peptide with the N-methyl the peptide The of a group a peptide has the of a number of membrane and proteolytic stability G. Med. Chem. Scholar). it in a of potential at the the role of at a binding and binding properties E. J. C. J. Biol. Chem. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar). are a number of of N-methyl peptides with a of M. Y. Chem. PubMed Scopus Google Scholar), Y. C.L. Y. D.L. J.C. C. Scopus Google Scholar), J. Chem. Scopus Google Scholar), and Scopus Google Scholar). of biologically active peptides by the inclusion of N-methyl an has been shown to enhance the M.A. E. B. E. G. A. J. Med. Chem. PubMed Scopus Google Scholar), the S.J. Murphy J. Med. Chem. 2001; PubMed Scopus (55) Google Scholar), and a peptide proteolytic in a M. A. B. S. D. P. Med. Biol. 2002; PubMed Scopus Google Scholar). This approach therefore the potential to optimize multiple In this study, we residues the previously peptide, R1, and the and properties of these and R1 an N-methyl group residues for which an N-methyl is not we used N-methylation J. Am. Chem. Scopus Google Scholar), a N-methyl of the R1 of each of these R1 that inclusion of a single N-methyl group was to dramatically improve AMA1 affinity, bioactivity, and peptide stability without the global peptide the of multiple N-methyl further increased AMA1 and improved of AMA1 from parasite This represents a in the of an effective anti-malarial compound to bind to AMA1 and parasite Furthermore, this to the development of a for and the of all from DMF, DCM, and from MTBD, and from The N-methyl and from was from and from and the as N-methyl residues by the of Miller and J. Am. Chem. Scopus Google Scholar). of the 1 was in was in and the was to the was and the was for this was and the was for The was with and and The of the was by the in and was for was and was with and with a of for this the was with and a was to a PubMed Scopus Google for the of The and was by in by the addition of a of in to which was This was for and to the This was for 1 and and with was for the of the PubMed Scopus Google Scholar). the was of the was and the was an N-methyl was to be the peptide the was in and the was to the with This was for The was by with a of and the in and the was for this the was with and with a of this involved was in the to the The was for the of a to the N-methyl group the The was and in the that the could not be used to the of and the N-methyl in this the T. Google was from and of the required peptide the group was and the was with and The was and with a of for The was and was to the which in the of the The peptide was and the peptide was by the The peptide was in and the was The peptides a an and and the molecular was by of the R1 peptide was as described A.M. M. M. and Scholar). cells the which the R1 peptide, in to by with by and of the in phosphate-buffered was in as previously described A.M. M. M. and Scholar). The parasite was as described previously C. J. Coppel R.L. R. Trop. Med. Hyg. Full Text PDF PubMed Scopus Google Scholar, PubMed Scopus Google Scholar), and parasites by of all but stage parasites C. J. PubMed Scopus Google Scholar). R1 peptide and R1 for to parasite as previously described A.M. Masciantonio R. J.K. A. Anders R.F. M. Infect. Immun. 2005; 73: PubMed Scopus Google Scholar). peptides in PBS, and was in to and parasites to each and for at in a of with PBS, parasites and by for parasite M.C. Wang J. Zhang Y.L. Miles A.P. Chitsaz F. Saul A. Long C.A. Miller L.H. Stowers A.W. Infect. Immun. 2002; 70: 6948-6960Crossref PubMed Scopus (221) Google Scholar). was at and the of invasion was peptide red blood cells peptide red blood cells with recombinant The antigen was in and at protein was by with PBS, and any with in R1 peptide or R1 applied to the in in the of a of R1 for 1 at with was by with was with antibodies was and the was at M. P. PubMed Scopus Google was used to the of the of R1 peptides and with AMA1 from of P. and binding at and as the AMA1 was The surface was with a at of a of of AMA1 to the surface was a approach of AMA1 to in the surface at of was 1 of The was by a of 1 to AMA1 as and In each at one of the cells the was used as for This was by a surface to the with protein binding in in at the binding a of peptide from to for and from to for and AMA1 at a of for 1 was by for which all of the peptide from the AMA1 surface and further was required. from the and at the of the by the The response of all was from all and to systematic in the and was used to and from the by to a binding that the 1998; PubMed Scopus Google Scholar). The was from the for for by peptides in of to a of The was to of most peptides a single major of indicating that any and of are shown in with of the in of and these peptides these have from The most of this is the peptide the N-methyl group at this has been previously in other peptides M. F. J. Am. Chem. PubMed Scopus Google Scholar, E. B. J. 2004; PubMed Scopus Google Scholar). of of major to with a of and at a nuclear Overhauser with a of at and nuclear Overhauser with a of at a was the M. V. V. J. PubMed Scopus Google Scholar). at and to an at or to the resonance. for and a S.J. J. Scholar, A.J. Morris J. PubMed Scopus Google as by S. G.J. J. 2000; 16: PubMed Scopus Google Scholar). and and C. M. P. J. PubMed Scopus Google Scholar). for the major of the peptides are in the and have been in the J. PubMed Scopus Google Scholar). from at and to as a could be the of S. F.M. J. PubMed Scopus Google Scholar), to the to No or for and of in and the of the T. P. J. Mol. Biol. 2002; PubMed Scopus Google Scholar). or of and the from the of was used in G. J. PubMed Scopus Google to a of the The with to a at the backbone of the The for each of with a of was the peptide which was and and the of the and this of of for each peptide for In all the or structural the R. M. J. Mol. PubMed Scopus Google and L. by 1 of to the and an of the in as of the and peptides and at in at and and each of was by of The for and for at in a was from the with of and by a The of the peptide to the was for each point and against the point peptide as a peptide of R1 R1 peptide of and its is shown in R1 a group at the backbone of each and have been 1 and a and N-methylation at would the peptide in the N-methyl of at the of the peptide, because of its to the Therefore, R1 by peptide as of the The of of N-methyl residues the of the are and for the these and by the of L. J.S. A.B. J. Chem. 68: PubMed Scopus Google and the peptide peptide N-methylation of other residues was required the of Miller and J. Am. Chem. Scopus Google was the group was from the to be and with the group This the and to by a as J. Am. Chem. Scopus Google Scholar). the group was by with and a for the these the R1 R1 peptide and the in the N-methyl in a AMA1 of R1 of these R1 for AMA1 was by the of each peptide to the of the R1 peptide with AMA1 by The peptides could be to the of was improved by the of a group at of residues and in a in AMA1 binding affinity, as by the of these peptides to R1 peptide from binding to of an N-methyl group at residues and AMA1 The and binding to R1 in this of R1 to the of N-methyl bioactivity, each R1 was for its to parasite invasion in vitro peptide, with the binding which are in R1 with N-methylation of which was to bind AMA1, parasite the its and parasite in However, because R1 peptide parasite at this any in by methylation could not be peptides of invasion therefore for in that the peptide was a invasion inhibitor R1, with the for this and effective the peptide AMA1 binding to This suggests that the binding not be to in and R1 the addition of a single group at and the of R1 to block parasite it was of to these could further improve R1 activity. Therefore, multiple a peptide with N-methyl at and and a peptide with N-methyl at and peptides with R1 peptide for binding to AMA1 to a to the peptide in these peptides parasite R1 of R1 strain of R1 with improved inhibitory and to the of these peptides for the form of AMA1, and binding to AMA1 from P. falciparum by and and The R1 peptide to AMA1 with a of methylation of the R1 peptide in an increased for the and R1 was not The for this increased appears to be of the peptide from AMA1 that the of N-methyl in the R1 peptide backbone the stability of the and R1 peptides and AMA1 from and of parasite by Although binding of all R1 peptides to these of AMA1 was to AMA1, the inclusion of multiple N-methyl in the R1 peptide in increased to and to for and AMA1, and by for the of R1 peptide with of P. falciparum and and by to binding that the was a used to for and are shown in used to for and are shown in used to for and are shown in used to for and are shown in not and and by to binding that the was a used to for and are shown in not in a of R1 the of N-methylation the of R1, and the R1 and The of the backbone and from are in The these backbone for each of the peptides and for R1 are in of these is that the backbone by N-methylation are to residues of the N-methyl which that N-methylation not any structural in The are with the previously described of R1, which the of residues is and the residues is A.M. Masciantonio R. J.K. A. Anders R.F. M. Infect. Immun. 2005; 73: PubMed Scopus Google Scholar). The residues in these are and and N-methylation at these would be to with of to and the The that and binding for AMA1 that the in not in the peptide, at not in in these are to represent the by the peptide, because peptides lacking any as in the of R1, are to a of in was of to the N-methyl to which is by the of is that the N-methyl which are to the backbone this we for N-methyl in the and of to the N-methyl The of are shown in the In the of N-methyl without N-methyl to the of R1, but inclusion of N-methyl and in the for an of in the of the N-methyl in a global However, because not in its was to that of of R1 important of peptides is to proteolytic degradation. the N-methyl that and can of the peptide to peptides a single N-methyl or or multiple N-methyl for stability in was that the R1 peptide and the peptide and of the peptide However, addition of a single group at or the inclusion of and in a in peptide in of the peptide N-methyl at and In this we have shown that a N-methyl of a 20-residue inhibitory peptide can of in the for the target protein and its N-methyl modifications in a in the proteolytic stability of the of backbone amides at can a number of a The of the group the and that peptide and potential at the site S. P. O. G. S. Med. Chem. 2004; PubMed Scopus Google Scholar). Furthermore, the in has the potential to improve peptide to N-methylation the of the R1 peptide with AMA1, a of R1 with a group to the backbone at was of the N-methyl not and the residues is not to the R1 peptide at as previously to the the of Miller and J. Am. Chem. Scopus Google Scholar). This would not the N-methyl was and could be by peptide the of all R1 peptide to with AMA1 and that N-methylation at or dramatically binding to of the previously R1 peptide A.M. Masciantonio R. J.K. A. Anders R.F. M. Infect. Immun. 2005; 73: PubMed Scopus Google that of these residues and are or a region of Because it is that the of a group a peptide backbone it is that this region is responsible for the of a is required for the of and to binding to has that this be the A.M. Masciantonio R. J.K. A. Anders R.F. M. Infect. Immun. 2005; 73: PubMed Scopus Google Scholar), to this be that the of a group potential at a and this to a of activity. it is that methylation at a single site R1 can dramatically the of the peptide for The R1 peptide has been to be an effective inhibitor of malaria parasite and the of N-methylation invasion was In the AMA1 binding of with inhibitory properties not parasite increased Thus, improved AMA1 binding to inhibitory properties. the of N-methylation peptides with a group to the backbone at multiple and in an in AMA1 affinity, as by and inhibitory as with the peptide indicating that single with the properties can further improve peptide Although the binding site by R1 has not been the peptide is to with the inhibitory mAbs and as as with the inhibitory peptide A.M. Masciantonio R. J.K. A. Anders R.F. M. Infect. Immun. 2005; 73: PubMed Scopus Google Scholar). This suggests that these all with a AMA1 binding a the antigen that appears to be the target of inhibitory The of and of P. falciparum AMA1 has been T. M. A. P. Murphy Anders R.F. Batchelor S. A. 2005; PubMed Scopus Google Scholar). important of this was the of a conserved by a of has been that this represent an important site that is from the immune by the the of AMA1 in with the inhibitory has that the is at one of the suggests that residues involved in of AMA1 be the of this conserved J.C. M.L. C. F. Blackman M.J. Kocken C.H. Thomas A.W. 2005; PubMed Scopus Google Scholar, A.M. Masciantonio R. J. Murphy Batchelor Anders R.F. M. Infect. Immun. PubMed Scopus Google Scholar, A.M. A. Murphy T. Anders R.F. M. Batchelor A.M. A. Murphy T. Anders R.F. M. Batchelor Google Scholar, C. Batchelor Thomas A.W. Blackman M.J. C. Batchelor Thomas A.W. Blackman M.J. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). Because R1 peptide with of these mAbs for binding to AMA1, it is that the peptide is the conserved these and is to with the binding of each mAb, binding a is in with the of other binding indicating that are to which by binding L. Full Text Full Text PDF PubMed Scopus Google Scholar, R.G. J. Mol. Biol. PubMed Scopus Google Scholar). Furthermore, have a common of the R1 and peptides is the of residues with the of these peptides to a site A.M. Masciantonio R. J.K. A. Anders R.F. M. Infect. Immun. 2005; 73: PubMed Scopus Google Scholar, Miles L.A. F. M. Anders R.F. A.M. M. PubMed Scopus Google Scholar). are currently to this and that the is the target of inhibitory This conserved represents an important target for the of anti-malarial therapeutics, because it is that the of be limited by a requirement to function. The of AMA1 is in the of this antigen as a therapeutic target. The R1 peptide has been shown previously to with the and of AMA1, but binding to AMA1 from the or parasite lines was we the strain of R1 the peptides multiple N-methyl a increased for the and allelic of AMA1, as with the peptide This suggests with further it be to AMA1 allelic variation by to the conserved region of the binding Because R1 an with of it is that N-methyl causes some in the of but global structural that the surface AMA1 to be by R1 is the of N-methylation a the and the of the N-methyl group to the without is that the of at some the of the R1 peptide to with the and that the in the improved binding to AMA1 from parasite the of N-methylation be in any of R1 this has that methylation can result in to proteolytic degradation. methylation of a peptide that of an human 1 has been shown previously to result in a in to M.J. J. Med. Chem. 2004; PubMed Scopus Google Scholar). We therefore a number of R1 for stability in was that the of a single group at as as multiple and to dramatically improve the of peptide in This is a because represents a to the of peptides as Although are some peptides in clinical rapid of or is a peptide that is currently in clinical for in human 1 R. S. R. S. Med. Chem. PubMed Scopus Google Scholar). However, in human of required to to in much effective in to the of this drug and indicating a requirement for improved S. B. L. E. D. D. T. M.A. M.S. Med. 1998; PubMed Scopus Google Scholar). of strategies to improve peptide stability therefore be of to a of peptide This has that the properties of a peptide that malaria parasite invasion of erythrocytes can be by systematic methylation of backbone N-methyl of a single improved target binding and and dramatically peptide stability in Furthermore, the of multiple N-methyl further increased target binding and that N-methyl of peptides the of and proteolytic stability to be the in peptide therapeutics, this approach could be applied to many lead peptides to optimize a number of to development of an effective We Anders and Murphy for of recombinant AMA1 and for with
53
Human Malaria Parasites in Continuous Culture
William Trager, James B. Jensen · Science · 1976 · 8K citations
The Xplor-NIH NMR molecular structure determination package
Charles D. Schwieters, John Kuszewski, Nico Tjandra et al. · Journal of Magnetic Resonance · 2003 · 2.4K citations
Life Sciences, Biophysics, Chemistry +10